Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1
574
about 2.8 years
18+
5 sites in MI, TX, VA
What this study is about
This trial is testing a treatment called RMC-5127 for people with advanced solid tumors that have the KRAS G12V mutation. The trial will evaluate how safe and effective this treatment is, as well as its effects on the body's ability to process the drug.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take RMC-5127
- 2.Take cetuximab
- 3.Take daraxonrasib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cetuximab
injection (Injection)
Primary: Dose Limiting Toxicities, Number of patients with adverse events (AEs)
Secondary: AUC concentrations of RMC-5127 and daraxonrasib, Cmax concentrations of RMC-5127 and daraxonrasib, Duration of Response (DOR), Half-Life of RMC-5127 and daraxonrasib, Objective Response Rate (ORR), Tmax concentration of RMC-5127 and daraxonrasib
Oncology